Advertisement

Loading...

Coherus Oncology, Inc.

CHRS•NASDAQ
Healthcare
Biotechnology
$1.75
$0.15(9.06%)
U.S. Market is Open • 10:05

Coherus Oncology, Inc. (CHRS) Stock Forecast & Price Predictions

Get the latest Coherus Oncology, Inc. (CHRS) stock forecast across short-term and long-term horizons. Meyka AI generates price predictions using advanced models trained on historical data. These forecasts are not investment advice but directional insights to help investors and traders plan strategies.

Model Information

The Forecast Prediction Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full Disclaimer

Monthly Forecast

Predicted Price$1.42
Change↓ $-0.33 (-18.62%)

Quarterly Forecast

Predicted Price$1.59
Change↓ $-0.16 (-8.88%)

Yearly Forecast

Predicted Price$1.52
Change↓ $-0.22 (-12.75%)

3 Years Forecast

Predicted Price$0.85
Change↓ $-0.90 (-51.53%)

5 Years Forecast

Predicted Price$0.15
Change↓ $-1.60 (-91.60%)

7 Years Forecast

Predicted Price$0.00
Change↓ $-1.75 (-100.00%)

Coherus Oncology, Inc. Stock Forecast Summary

Coherus Oncology, Inc. (CHRS) stock is currently priced at $1.75. Based on Meyka AI predictions, the short-term outlook is bearish, with momentum pointing higher. The 1-month projection suggests a move toward $1.42.

In the long term, CHRS shows a bearish trend. The 2027 forecast points to $1.52 (-12.75% change), while the 2031 forecast suggests $0.15 (-91.60% change). Looking 7 years ahead, projections estimate the stock could trade near $0.00, a -100.00% change from today’s price.

Overall Sentiment

Bearish

Short-Term Outlook

Bearish

Long-Term Outlook

Bearish

This mix indicates that Coherus Oncology, Inc. stock is expected to face downside risk over the coming years.

Coherus Oncology, Inc. yearly Price Forecast Chart

Explore the yearly forecast chart for CHRS, which maps expected price movement, support levels, and resistance targets. The dropdown lets you view forecasts across multiple horizons, from short-term daily trends to 7-year projections, helping investors evaluate Coherus Oncology, Inc. over different timeframes.

No forecast data available

No prediction data found for this time period.

empty-state-iconForecasting data is not available for CHRSForecasting details for CHRS are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Coherus Oncology, Inc. Stock Forecast 2026

The forecast for Coherus Oncology, Inc. (CHRS) in 2026 suggests a price of $1.52, representing a -12.75% move from today’s price.

Average Target: $1.52

Market Outlook: bearish based on current trend indicators.

Key Drivers in 2026:
  • Earnings growth projections.
  • Competitive performance in the Healthcare.
  • Macroeconomic factors such as interest rates and inflation.

Coherus Oncology, Inc. Stock Forecast 2030

By 2030, Meyka AI projects CHRS could trade near $0.15, showing a potential -91.60% compared to current levels.

Average Target: $0.15

Market Outlook: bearish.

What could influence the 2030 forecast:
  • Technological innovation and product cycles.
  • Expansion into global markets.
  • Long-term investor sentiment toward Coherus Oncology, Inc..

Frequently Asked Questions